Molecular monitoring of the treatment of patients with BCR/ABL (+) chronic myelogenous leukemia

Revista de Investigacion Clinica

Volumn 53, Issue 3, 2001, Pages 235-239

  Ruiz Argüelles, Guillermo J ^a,b,d   López Martínez, Briceida ^a   Ramírez Cabrera, Juan Manuel ^a   Reyes Núñez, Virginia ^b   Rodríguez Cedeño, Hilze M ^a   Garcés Eisele, Javier ^b,c  

^a Centro de Hematología   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c UNIVERSIDAD DE LAS AMÉRICAS PUEBLA   (Mexico)

^d CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

BCR ABL; Chronic; Leukaemia; Molecular; Myelogenous

Indexed keywords

BCR ABL PROTEIN;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; BLOOD; CHRONIC MYELOID LEUKEMIA; FEMALE; FOLLOW UP; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035346607     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9.
2. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Pérez-Romano B, Ruiz-Argüelles A, Ramírez-Cisneros F, López-Martí-nez B, López-Tapia JD, Rivadeneyra-Espinoza L. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: A prospective study in a single institution. Rev Invest Clin Mex 2000; 52: 118-24.
3. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-8.
4. Chronic Myeloid Leukemia Trialists's Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616-24.
5. O' Brien SG. Autografting for chronic myeloid leukemia. Bailliere's Clin Haematol 1997; 10: 369-82.
6. Goldmann JM. Treatment of chronic myeloid leukemia: Some topical questions. Bailliere's Clin Haematol 1997; 10:405-420.
7. Melo JV. CML: Molecular patophysiology and potential new targets for therapy. In: Schlechter GP, Berliner N, Telen MJ (Editors): Hematology 2000. The American Society of Hematology Education Program Book. Washington, U.S.A. 2000. p. 90-4
8. Ruiz-Argüelles GJ, Lobato-Mendizábal E, Ruiz-Argüelles A, Pérez-Romano B, Arizpe-Bravo D, Marín-López A. Non-cryo-preserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: Long term results. Arch Med Res 1999; 30: 380-4.
9. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25: 131-3.
10. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001. (66: 241-4).
11. Goldman JM. Chronic myeloid leukaemia. In: Whittaker JA, Holmes JA (editors): Leukaemia and related disorders. Blackwell Science; Oxford: 1998. p. 252-69.
12. Falcón E, Ruiz E, Báez E, Garcés O, Ignacio G, Gómez-Morales E, Madrid V, Herrera P, Delgado-Lamas JL, Rubio ME, Pizzuto J, Rico BC, Rodríguez-Carrillo J, Ovilla R, Arana RM, Koffman S. Incidencia en el tipo de rearreglo molecular BCR/ABL en pacientes con leucemia mieloide crónica. Gac Med Mex 2000; 136 (Suppl 1): S178.
13. Franklin IM, Mills K. Chronic myeloid leukemia. In: Provan D, Gribben J (editors): Molecular hematology. Blackwell Science; Oxford: 2000. p. 61-74.
14. Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Argüelles A. Molecular follow-up of patients with promyelocytic leukaemia treated with all trans-retinoic acid. Clin Lab Haematol 1998; 20: 173-6.
15. San-Miguel JF, Orfao A, Pongers-Willemse MJ, van Dongen JM. Detection of minimal residual disease in acute leukemia. In: Willemse R, Mc Arthur JR, Degos L (editors). Haematology 1998. Education Program of the 27th Congress of the International Society of Hematology. p. 22-9.
16. Giralt S. Updates on unrelated donor transplantation, donor lymphocyte infusions and non-ablative stem cell transplantation. In: Schlechter GP, Berliner N, Telen MJ (Editors): Hematology 2000. The American Society of Hematology Education Program Book; Washington, U.S.A: 2000. p. 97-101.
17. Ruiz-Argüelles GJ, Gómez-Almaguer D, Velázquez-Ferrari MA. Transplantes alogénicos "heroicos" de células hematopoyéticas de sangre periférica empleando un esquema de acondicionamiento no mieloablativo en dos pacientes con leucemias en estadios avanzados. Gac Med Mex 2000; 136 (Suppl 2): S216.
18. Ruiz-Argüelles GJ. Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica 2000; 85: 1233-4.
19. Velázquez-Hernández BM, Ruiz-Argüelles GJ, Apreza-Molina MG. Resultados a largo plazo del tratamiento de pacientes con leucemia granulocítica crónica con busulfán y/o hidroxiurea. Estudio prospectivo. Med Int Méx 1996; 12: 97.
20. Druker BJ, Tamura S, Buchdunger E.: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR/ABL positive cells. Nat Med 1996; 2:561-3
21. Ruiz-Argüelles GJ, Velázquez BM, Apreza-Molina MG, Pérez-Romano B, Ruiz-Reyes G, Ruiz-Argüelles A. Chronic lymphocytic leukemia is infrequent in Mexican mestizos. Int J Hematol 1999; 69: 253-5.